James M Gallo, PharmD, PhD
- ADJUNCT PROFESSOR | Pharmacological Sciences
I'm a pharmacokineticist focused on the experimental therapeutics of anticancer drugs. In particular we use systems-based pharmacokinetic [PK] and pharmacodynamic [PD] – systems pharmacology - approaches to advance drug development and improve drug therapy of brain tumors. We hope to identify new chemotherapeutic strategies and enhance the translational foundation of preclinical to clinical research.
Gallo Laboratory website
Multi-Disciplinary Training AreaPharmacology and Therapeutics Discovery [PTD]
BS, Massachusetts College of Pharmacy
PharmD, University of Florida
PhD, University of Arizona
Systems Pharmacology of Brain Tumors
Our lab is focused on pharmacokinetic [PK]- and pharmacodynamic [PD]-directed brain tumor chemotherapy. We have incorporated systems-based methods with PK/PD methods to derive cell-type specific PK/PD and enhanced PD models that link PK and PD information at the cell and molecular scale. Ongoing projects concern anticancer drug discovery and development, oncometabolites, epigenetic modulators and tumor heterogeneity. The projects utilize a diverse array of methods that allow us to build mechanistic PK/PD models of anticancer drugs that they are scalable from preclinical models to patients. The ultimate objective of our work is to discover new targets and drugs and means to optimize multi-drug chemotherapeutic regimens.
For more information, please visit the Gallo laboratory website.
Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.. Clin Cancer Res 2007 Jul; 13(14): 4271-4279.
Wang S, Zhou Q, Gallo JM. Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.. Mol Cancer Ther 2009 Jun; 8(6): 1438-1447.
Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM. Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts. The Journal of pharmacology and experimental therapeutics 2012 Nov; 343(2).
Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. The AAPS journal 2011 Mar; 13(1).
Lv H, Zhang X, Sharma J, Reddy MV, Reddy EP, Gallo JM. Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. The AAPS journal 2013 Jan; 15(1).
Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. Merging systems biology with pharmacodynamics. Science translational medicine 2012 Mar; 4(126).
Gallo JM. Physiologically based pharmacokinetic models of tyrosine kinase inhibitors: a systems pharmacological approach to drug disposition. Clinical pharmacology and therapeutics 2013 Mar; 93(3).
Sharma J, Lv H, Gallo JM. Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma. Cancer research 2013 Aug; 73(16).
Birtwistle MR, Mager DE, Gallo JM. Mechanistic vs. Empirical network models of drug action. CPT: pharmacometrics & systems pharmacology 2013; 2.
Zhang XY, Birtwistle MR, Gallo JM. A General Network Pharmacodynamic Model-Based Design Pipeline for Customized Cancer Therapy Applied to the VEGFR Pathway. CPT: pharmacometrics & systems pharmacology 2014; 3.
Sane R, Wu SP, Zhang R, Gallo JM. The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain. Drug metabolism and disposition: the biological fate of chemicals 2014 Apr; 42(4).
Ballesta A, Zhou Q, Zhang X, Lv H, Gallo JM. Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors. CPT: pharmacometrics & systems pharmacology 2014; 3.